bioAffinity Technologies, Inc. (BIAF)
NASDAQ:BIAF
Want to see BIAF full AI Analyst Report?
Top Page
bioAffinity Technologies, Inc.
(NASDAQ:BIAF)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
â–²(16.28% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance (large ongoing losses, heavy cash burn, and balance-sheet erosion) and bearish technicals (below key moving averages with negative MACD). Corporate events are a relative positive due to reported sales acceleration and study progress, but capital-structure actions add dilution risk, and valuation is hard to support with negative earnings.
Positive Factors
High clinical performance of noninvasive test
CyPath Lung's sputum-based flow cytometry plus AI shows high sensitivity and specificity, a durable clinical advantage that can reduce invasive biopsies, build clinician trust, and support guideline and payer engagement—strengthening long-term adoption and referral workflows.
Negative Factors
Heavy cash burn and negative free cash flow
Persistent negative operating and free cash flow (~-$10.9M TTM) means the business depends on external funding to sustain operations. Continued cash burn raises financing and timing risk, potentially forcing dilutive capital raises before commercialization fully self-funds growth.
Read all positive and negative factors
Positive Factors
Negative Factors
High clinical performance of noninvasive test
CyPath Lung's sputum-based flow cytometry plus AI shows high sensitivity and specificity, a durable clinical advantage that can reduce invasive biopsies, build clinician trust, and support guideline and payer engagement—strengthening long-term adoption and referral workflows.
Read all positive factors
bioAffinity Technologies, Inc. (BIAF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.53M
Dividend YieldN/A
Average Volume (3M)5.91M
Price to Earnings (P/E)―
Beta (1Y)-3.65
Revenue Growth-35.75%
EPS Growth47.29%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-12.47
Shares Outstanding4,534,906
10 Day Avg. Volume6,249,809
30 Day Avg. Volume5,911,951
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.28
Price to Sales (P/S)0.33
P/FCF Ratio-0.22
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue0.99
Enterprise Value/Gross Profit4.49
Enterprise Value/Ebitda-0.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.1
Revenue Forecast (FY)$7.31M
bioAffinity Technologies, Inc. Business Overview & Revenue Model
Company Description
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researche...
How the Company Makes Money
bioAffinity Technologies generates revenue primarily by commercializing its diagnostic testing. The core revenue stream is fees collected per test performed for CyPath® Lung, which are typically realized through providing the test as a clinical se...
bioAffinity Technologies, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.66M | 6.16M | 9.36M | 2.53M | 4.80K | 0.00 |
| Gross Profit | 1.25M | 1.43M | 3.38M | 791.62K | 4.34K | -4.82K |
| EBITDA | -15.35M | -10.07M | -8.33M | -7.63M | -5.61M | -5.32M |
| Net Income | -15.88M | -14.91M | -9.04M | -7.94M | -8.15M | -6.33M |
Balance Sheet | ||||||
| Total Assets | 7.95M | 10.96M | 6.51M | 8.22M | 12.18M | 1.45M |
| Cash, Cash Equivalents and Short-Term Investments | 3.10M | 6.45M | 1.11M | 2.82M | 11.41M | 1.36M |
| Total Debt | 1.38M | 1.16M | 1.50M | 1.58M | 251.75K | 11.36M |
| Total Liabilities | 4.28M | 3.68M | 3.91M | 3.37M | 1.14M | 17.24M |
| Stockholders Equity | 3.66M | 7.28M | 2.60M | 4.86M | 11.04M | -15.79M |
Cash Flow | ||||||
| Free Cash Flow | -10.87M | -9.39M | -7.34M | -6.06M | -4.29M | -2.05M |
| Operating Cash Flow | -10.91M | -9.33M | -7.26M | -6.04M | -4.07M | -2.05M |
| Investing Cash Flow | -15.44K | -60.57K | -79.08K | -2.21M | -219.99K | 0.00 |
| Financing Cash Flow | 13.58M | 14.73M | 5.63M | -344.98K | 14.34M | 3.33M |
bioAffinity Technologies, Inc. Technical Analysis
Negative
1.29
Price Trends
2.74
Negative
1.94
Negative
2.94
Negative
Market Momentum
-0.27
Positive
34.08
Neutral
16.32
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Negative. The current price of 1.29 is below the 20-day moving average (MA) of 2.04, below the 50-day MA of 2.74, and below the 200-day MA of 2.94, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 34.08 is Neutral, neither overbought nor oversold. The STOCH value of 16.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIAF.
bioAffinity Technologies, Inc. Risk Analysis
bioAffinity Technologies, Inc. disclosed 76 risk factors in its most recent earnings report. bioAffinity Technologies, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
bioAffinity Technologies, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $6.77M | ― | -174.16% | ― | 33.26% | 49.65% | |
44 Neutral | $7.05M | -1.06 | -537.60% | ― | ― | 98.32% | |
43 Neutral | $7.53M | -1.19 | -245.18% | ― | -35.75% | 47.29% | |
41 Neutral | $4.47M | >-0.01 | -496.37% | ― | -87.25% | 87.10% |
* Healthcare Sector Average
BIAF
bioAffinity Technologies, Inc.
1.62
-6.64
-80.39%
NDRA
ENDRA Life Sciences
5.35
2.22
70.93%
INBS
Intelligent Bio Solutions
2.63
-10.27
-79.61%
ISPC
iSpecimen
3.57
-42.03
-92.17%
BGLC
BioNexus Gene Lab Corp
2.02
-0.81
-28.62%
bioAffinity Technologies, Inc. Corporate Events
Business Operations and StrategyFinancial Disclosures
bioAffinity CyPath Lung Test Sales Surge Sharply
Positive
May 12, 2026
On May 12, 2026, bioAffinity Technologies reported that unit sales of its CyPath® Lung diagnostic test reached a record monthly level and rose nearly 300% in April 2026 versus April 2025, based on preliminary unaudited data. Management said t...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder MeetingsStock Split
bioAffinity Shareholders Approve Equity Plan and Capital Measures
Positive
Apr 30, 2026
At its April 30, 2026 annual meeting, bioAffinity Technologies’ shareholders approved a significant expansion of the 2024 Equity Incentive Compensation Plan, raising the share reserve from 66,666 to 1,000,000, and re-elected six directors wh...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Highlights CyPath Lung Case Avoiding Unnecessary Biopsy
Positive
Apr 14, 2026
On April 14, 2026, bioAffinity Technologies reported a clinical case in which its CyPath® Lung sputum test helped guide management of a 70-year-old high-risk patient whose imaging and risk models suggested a 30-millimeter nodule was likely ma...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Showcases CyPath Lung Test at Cleveland Clinic
Positive
Apr 7, 2026
bioAffinity Technologies, Inc., a biotechnology firm specializing in noninvasive lung cancer diagnostics, markets its CyPath® Lung test as a CLIA‑overseen Laboratory Developed Test through its subsidiary Precision Pathology Laboratory S...
Business Operations and StrategyFinancial Disclosures
bioAffinity Reports Surge in CyPath Lung Test Sales
Positive
Apr 1, 2026
bioAffinity Technologies reported on April 1, 2026, that first-quarter 2026 unit sales of its CyPath® Lung diagnostic test rose 146% year over year based on preliminary unaudited data, surpassing internal projections and signaling stronger ph...
Business Operations and StrategyRegulatory Filings and Compliance
bioAffinity Technologies Posts New Investor Presentation Materials
Neutral
Mar 26, 2026
bioAffinity Technologies, Inc., a Delaware corporation, reported that it has prepared a set of presentation materials covering its operations and performance for use by management in investor and stakeholder presentations. These materials were pos...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Launches Virtual Roundtables on CyPath Lung Adoption
Positive
Mar 25, 2026
On March 25, 2026, bioAffinity Technologies announced it will host the first in a series of live virtual physician roundtables exploring the integration of its CyPath® Lung diagnostic test into pulmonary practice. The inaugural session, sched...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Showcases CyPath Lung Case Study in Diagnostics
Positive
Mar 17, 2026
bioAffinity Technologies, Inc., a biotechnology company specializing in noninvasive lung cancer diagnostics, on March 17, 2026 released a clinical case study on its CyPath® Lung test. CyPath® Lung uses flow cytometry, artificial intellig...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Launches Major Lung Cancer Detection Study
Positive
Mar 10, 2026
On March 10, 2026, bioAffinity Technologies announced the start of a 2,000-patient, large-scale longitudinal clinical study to evaluate the clinical performance of its CyPath® Lung technology for early detection of lung cancer in high-risk in...
Executive/Board ChangesShareholder Meetings
bioAffinity Announces Upcoming Departure of Two Board Directors
Neutral
Mar 6, 2026
bioAffinity Technologies, Inc. disclosed that on March 5, 2026, directors Robert Anderson and Roby Joyce informed the Board they will not stand for re-election when their current terms end at the 2026 Annual Meeting of Stockholders, scheduled for ...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Showcases Sputum-Based Platform for Personalized Asthma Care
Positive
Mar 4, 2026
On March 1, 2026, bioAffinity Technologies presented new research at the American Academy of Allergy, Asthma and Immunology annual meeting in Philadelphia showing its sputum-based diagnostic platform can identify antibody drug receptors for leadin...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Launches New CyPath Lung Validation Study
Positive
Feb 25, 2026
On February 25, 2026, bioAffinity Technologies announced a new validation study with Brooke Army Medical Center to test the clinical utility of its CyPath® Lung diagnostic on sputum samples obtained via tracheal and bronchial suctioning. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.